Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
Pierre Squifflet, Everardo D Saad, Murat Kurt et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated potential surrogate endpoints for overall survival (OS) in 1865 treatment-naive metastatic melanoma patients receiving anti-PD-1 regimens. The study found that objective response rate (ORR) had a strong correlation with OS (OR 12.29), while progression-free survival (PFS) and time to next treatment or death (TNTD) showed moderate correlations. The analysis utilized individual-patient data from four randomized controlled trials.
Key findings
- ORR showed a strong individual-level association with OS (OR 12.29, 95% CI 9.78 to 14.80).
- PFS had a strong individual-level correlation with OS (ρ = 0.72, 95% CI 0.70 to 0.73).
- TNTD demonstrated a strong individual-level correlation with OS (ρ = 0.77, 95% CI 0.76 to 0.78).
- At the trial level, all candidate surrogates showed moderate predictive abilities for OS.
Why it matters
Identifying reliable surrogate endpoints for overall survival can accelerate the development and approval of new therapies for metastatic melanoma, potentially improving patient access to effective treatments.